An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab
- 1 February 2012
- journal article
- Published by Elsevier BV in Molecular Immunology
- Vol. 50 (3), 134-141
- https://doi.org/10.1016/j.molimm.2012.01.001
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activationBlood, 2008
- The potential utility of B cell-directed biologic therapy in autoimmune diseasesRheumatology International, 2007
- Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minorNature Biotechnology, 2006
- Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximabBlood, 2006
- Flow cytometric assay for determination of FcγRIIIA-158 V/F polymorphismJournal of Immunological Methods, 2005
- How does B cell depletion therapy work, and how can it be improved?Annals Of The Rheumatic Diseases, 2005
- A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cellsBlood, 2004
- Rituximab-Dependent Cytotoxicity by Natural Killer CellsCancer Research, 2004
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002
- The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1HMolecular Immunology, 1995